Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
- {- {- k2 Y$ P$ r: d% A& [" E+ _2 t
% e& @- J; }4 c% ^# _' s
Sub-category:/ k+ Y" U# j5 t1 N- P6 b4 h" J9 j
Molecular Targets
6 g W9 ]. E4 n0 X: ^( s8 W2 g) a3 p6 a' i2 ^
2 M* e7 Z, a; K) rCategory:
% ] w( F6 s( p. uTumor Biology , S j2 r8 v7 L! }
* i9 x9 g# d, X+ t) n
m0 u$ {) l! k/ t
Meeting:
3 d3 ]! J+ c( a1 J0 ~0 f* v" x2011 ASCO Annual Meeting
% h* l/ h. @- `, \
9 o/ r- S/ s, P- Z
A4 B. W: I/ _" F- { qSession Type and Session Title:
( M) S) C2 {/ b, S. R% X6 hPoster Discussion Session, Tumor Biology
8 A4 Z% L$ X5 j9 x3 g- r3 m: s
: p( `% z8 m$ r# U6 K8 Y: ^9 k
" k, V3 L' H VAbstract No:! Q. i( e/ D! |5 H: P' j
10517
6 Z$ X8 c3 m9 E8 x, A8 p5 }) R
& L- R g2 H* o F, j
/ ?5 } F; C9 r: a& J$ D n' nCitation:
+ w2 m: ?& |! a9 D" U& B0 D* vJ Clin Oncol 29: 2011 (suppl; abstr 10517)
4 S* J1 @2 U- D0 ?( f3 e& q, z3 E6 r& h; f
" e; l& L3 F/ ^$ b9 w' q, M; GAuthor(s):. q4 F7 }; I6 D: L) w
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China , o9 c L' n9 Y
5 ~, q% H% @" V
9 l% [2 t. x. n. p. Z( r
. n: B, _! B* A" n' O
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
: I8 u8 Y& n$ Y
2 K: {( w0 s- W% U) q, TAbstract Disclosures' ?5 u, T4 i! X1 ` r
, @9 |$ k) f* j# K* H. \Abstract:
6 n. e' W0 y. w: \# B# Z2 i2 M ?. ^8 W9 ` U+ q
9 x; u/ U* y7 D* K) }* P+ G( D. O
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
2 S) ?0 ^+ D/ N5 p d) I0 W
5 P6 w+ o# A; ]; z+ H 4 Z3 j, E/ p' z: z& l- `
|
肺鳞癌骨转移
求教各位，家父肺鳞癌，21年手术，23年复发，之后进行放疗化疗。结束后一直靠恩沃利单
求助 K药和替雷利珠如何选择
父亲9月刚查出非小细胞低分化癌伴随左肾上腺和第10胸椎转移PDL1高表达(TPS=90%) SMARC
pet-ct结果，请大佬们受累给看一下。
节后在心胸外科住院，马上安排了pet-ct，今天拿到报告，请大佬们受累给解读一下，结节
依沃西用药后，该怎么办？
依沃西用药后，该怎么办？
我爸爸于2024年7月确诊肺鳞癌，整个治疗过程如附件里表格
请教：奥西耐药后续治疗
父亲50岁，近期频繁咳嗽。
治疗情况：
2023年1月-2024年10月
EGFR19 奥西替尼靶向治疗
显身卡
